Artemisinin partial resistance in Ugandan children with complicated malaria
Document Type
Article
Department
Paediatrics and Child Health (East Africa)
Abstract
Intravenous artesunate, a semisynthetic derivative of artemisinin, is the World Health Organization (WHO)–recommended treatment for malaria requiring parenteral treatment. Malaria caused 608 000 deaths in 2022, mostly due to Plasmodium falciparum.1 Artemisinin partial resistance due to Pfkelch13 variations has been documented in East Africa in uncomplicated malaria2,3 but not in complicated malaria. We assessed artemisinin partial resistance, Pfkelch13 variations, and malaria recrudescence in Ugandan children with complicated malaria.
Publication (Name of Journal)
JAMA
DOI
https://doi.org/10.1001/jama.2024.22343
Recommended Citation
Henrici, R.,
Namazzi, R.,
Kato, C.,
Aliwuya, S.,
Lima-Cooper, G.,
Conroy, A.,
Dombrowski, J.,
Pratt, S.,
Campino, S.,
Opoka, R.
(2024). Artemisinin partial resistance in Ugandan children with complicated malaria. JAMA, 1-1.
Available at:
https://ecommons.aku.edu/eastafrica_fhs_mc_paediatr_child_health/555